跳至主要内容
临床试验/EUCTR2017-003779-75-ES
EUCTR2017-003779-75-ES进行中(未招募)1 期

Randomized clinical trial to assess the impact of treatment with empagliflozine on systemic inflammatory and renal parameters in patients with Diabetes Mellitus type 2 and ischemic heart disease.

Hospital Universitario La Paz0 个研究点目标入组 80 人开始时间: 2017年10月13日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Patients diagnosed with type 2 DM with poor metabolic control (glycosylated hemoglobin> 6.5%)
  • 2. Patients who have suffered an acute myocardial infarction or who have undergone a coronary revascularization procedure within 30 days prior to the start of the study.
  • 3. Over 18 and under 85
  • 4. Treatment with any hypoglycaemia including insulin.
  • 5. Left ventricular ejection fraction preserved (LVEF> 40%)
  • 6. Patients who have signed their consent to participate in the study
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 60
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • 1. Patients with type 1 DM.
  • 2. Previous or current treatment with an SGLT2 inhibitor.
  • 3. Creatinine clearance <60 ml / min / 1.73m2.

研究者

相似试验